Evis Hursever, Ph.D.

CEO

London

Evis Hursever joined EW in 2011, became Managing Director in 2019 and CEO in 2024.

Dr. Hursever led EW’s growth equity investments in Cognate Bioservices (acquired by Charles River Laboratories) and Laboratoires Majorelle, and has played a key role and served on the Board of Directors of EW growth equity portfolio companies EUSA Pharma II (acquired by Recordati), Biotoscana (acquired by Knight Therapeutics), Grundium and Germfree Laboratories.

Prior to joining EW, Dr. Hursever had over 10 years of experience in the healthcare industry. She was a senior manager in the European life sciences and healthcare team at LEK Consulting, a management consulting company. She was involved in several business transactions in the healthcare space, developed growth strategies for several pharmaceutical companies, and led numerous due diligence assignments for private equity firms in the healthcare industry. Prior to LEK Consulting, Dr. Hursever worked in the healthcare investment banking team at Merrill Lynch International providing M&A advisory services to a broad range of life sciences and healthcare companies.

Dr. Hursever received her Bachelor of Arts degree from Macalester College and her PhD degree from the University of Pennsylvania.